#danazol

various medication blinkies - 150x20px

Abstract

Autoimmune progesterone dermatitis (APD) is a rare cyclic premenstrual reaction to progesterone produced during the luteal phase of the menstrual cycle. The clinical symptoms of the APD overlap with other forms of dermatosis such as erythema multiforme, eczema, fixed drug eruption, urticaria, and angioedema. APD symptoms usually develop in 3 to 10 days before the menstruation and resolve in 1 to 2 days       after the menstruation ceases. Eczema developed on body of a 22-year-old female 7 days prior to her menstrual period. She was diagnosed with allergic contact dermatitis and prescribed with topical steroids. Her skin conditions did not improve and were associated with her menstrual period. An intradermal test using progesterone was performed, which was positive. She was treated with oral danazol and the symptoms were resolved. This is a typical case of APD triggered by increased sensitivity to endogenous progesterone.

Keyword: Autoimmune progesterone dermatitis, hypersensitivity progesterone, danazol, eczema.

Introduction

Autoimmune progesterone dermatitis (APD) is a rare form of hypersensitivity (HS) to progesterone (PG). It is characterized by recurrent skin eruptions during the luteal phase of the menstrual period, coinciding with peak levels of endogenous PG.1 Many manifestations have been reported including cyclical urticaria, vesiculobullous eruptions, erythema multiform, eczema, maculopapular eruptions, purpura/petechiae, and stomatitis.2 The histopathologic findings are non-specific and often correlate with the lesion morphology.3 The pathogenetic mechanism of APD has not yet been known. The APD is diagnosed and confirmed with either an immediate or delayed skin and/or systemic reaction to an intradermal progesterone (IDP) injection. Treatment is generally focused in alleviating the symptoms during each episode and taking oral contraceptive (OCPs).

Case report

A 22 – year – old woman, PARA 0000, having regular menstrual period and no previous medical history. She presented with a 2-year history of pruritic erythema which is located only on her back and closely associated with the menstrual period. The red rash became worse 5 days before menstruation and better 3 days after menstruation. A lichenoid papule is on her back, with a size of 15cmx5cm, clearly demarcated, without scabs, and much itching (Figure 1). She didn’t have vaginal bleeding, no history of using cosmetics or chemicals. Blood test results (complete blood count, basic blood chemistry) were within normal limits. An endodermal test with progesterone 50mg/ml was performed for the patient. The results were positive after 20 min both with 1:10 and 1:100 concentrations (Figure 3). The patient was treated with antihistamines (levcertizin 5 mg/day) and methylprednisolone 16 mg/day. After 2 days of treatment, the itchy papule did not improve. The patient was supplemented with Danazol 200mg/day. After 2 days of Danazol treatment, symptoms and redness were significantly reduced (Figure 2). In the following month, with patient taking Danazol 1 week before the period, the rash did not recur.

Discussion

Autoimmune progesterone dermatitis is a rare skin condition with varying morphology, appearing on a monthly basis during the luteal phase of the menstrual cycle. Symptoms of APD correlate with progesterone levels during the luteal phase of the menstrual cycle. The first documented case of APD was in 1921, in which a patient’s premenstrual serum caused acute urticarial lesions. In addition, it was shown that the patient’s premenstrual serum could be used to desensitize and improve her symptoms. Progesterone levels gradually rise after ovulation, reaching a peak concentration about 7 days before menstruation, then decreasing 1 to 2 days after menses, when there is a spontaneous resolution of APD.4,5 In this condition, symptoms was found 5 days before menstruation, coincide with the peak progesterone’s concentration. The major mechanism is considered to be the exposure to exogenous and/or endogenous progesterone causing hypersensitivity reaction that leads to clinical manifestation of this disease.1 The pathogenesis of APD remains unclear. Sexhormones modulate the immune and inflammation and inflammatory functions of cells, including mast cell degranulation. Several studies point to an autoimmune mechanism mediated by Th1 lymphocytes targeting endogenous progesterone, as in delayed hypersensitivity reactions. In women undergoing exogenous progesterone prior to APD diagnosis, Th2 cells and immunoglobulin IgE may also play a role.6

The clinical features of APD vary and thus far, about 80 cases have been reported in the literature. The most common clinical manifestations were eczema, urticaria, angioedema and erythema multiforme.5,7,8 Presentation of this case as an eczema is common symptom. Initially, this patient was considered to have allergic contact dermatitis. Because of its polymorphic characteristics, physicians can easily misdiagnose and thus treat this condition incorrectly.

The diagnostic criteria for APD proposed by Warin8 include 1) skin lesion associated with menstrual cycle (premenstrual flare); 2) a positive response to the progesterone intradermal test or reproducibility of the rash with the intramuscular test; and 3) symptomatic improvement after inhibiting progesterone secretion by suppressing ovulation. This patient has full 3 criteria for diagnosis. The intradermal test can support the diagnosis of APD based on the symptoms; on the contrary, in asymptomatic women, a positive intradermal test can result in false negative; therefore, this test might not be the most efficient diagnostic criteria for diagnosis of APD.

Treatment of APD is achieved mainly through suppressing ovulation. The first line of therapy is combined with oral contraceptives. The use of GnRH agonists has been reported successful in treatment. Another therapeutic agent used to suppress ovulation and improve symptoms is tamoxifen.5 Alkylated steroids, such as stanozolol and danazol, have been used to suppress ovulation, occasionally in combination with low dose corticosteroids.9 In this case, we have prescribed danazol to the patient 7 days before each menstrual cycle to 3 days after their period. The patient had a complete response and no relapse.

Conclusion

Danazol, commonly sold under the brand name Danocrine, is a synthetic steroid used to treat various hormonal and reproductive conditions. Primarily, it is prescribed for conditions such as endometriosis, fibrocystic breast disease, and to prevent attacks of hereditary angioedema. Danazol works by reducing the production of certain hormones, which helps alleviate symptoms of these conditions.

For those in need of Danazol, DiRx offers a convenient and affordable option for the medication without requiring insurance. You can explore cost-saving options and get your medications delivered directly to your home at DiRx.

How Danazol (Danocrine) Works

Danazol works by modifying the production of pituitary gonadotropins, which helps reduce estrogen levels in women and testosterone levels in men. This reduction in hormones alleviates conditions such as endometriosis (where uterine-like tissue grows outside the uterus) and fibrocystic breast disease (a non-cancerous breast condition). It is also used in hereditary angioedema, a genetic disorder that causes swelling in various parts of the body, by preventing episodes of swelling.

Danazol's effect on hormone regulation makes it highly effective in managing these medical conditions. To access Danazol easily and affordably, visit DiRx for competitive prices and convenient delivery.

ABSTRACT

Autoimmune progesterone dermatitis (APD) is a rare cyclic premenstrual reaction to progesterone produced during the luteal phase of the menstrual cycle. The clinical symptoms of the APD overlap with other forms of dermatosis such as erythema multiforme, eczema, fixed drug eruption, urticaria, and angioedema. APD symptoms usually develop in 3 to 10 days before the menstruation and resolve in 1 to 2 days       after the menstruation ceases. Eczema developed on body of a 22-year-old female 7 days prior to her menstrual period. She was diagnosed with allergic contact dermatitis and prescribed with topical steroids. Her skin conditions did not improve and were associated with her menstrual period. An intradermal test using progesterone was performed, which was positive. She was treated with oral danazol and the symptoms were resolved. This is a typical case of APD triggered by increased sensitivity to endogenous progesterone.

Keyword: Autoimmune progesterone dermatitis, hypersensitivity progesterone, danazol, eczema.

INTRODUCTION

Autoimmune progesterone dermatitis (APD) is a rare form of hypersensitivity (HS) to progesterone (PG). It is characterized by recurrent skin eruptions during the luteal phase of the menstrual period, coinciding with peak levels of endogenous PG.1 Many manifestations have been reported including cyclical urticaria, vesiculobullous eruptions, erythema multiform, eczema, maculopapular eruptions, purpura/petechiae, and stomatitis.2 The histopathologic findings are non-specific and often correlate with the lesion morphology.3 The pathogenetic mechanism of APD has not yet been known. The APD is diagnosed and confirmed with either an immediate or delayed skin and/or systemic reaction to an intradermal progesterone (IDP) injection. Treatment is generally focused in alleviating the symptoms during each episode and taking oral contraceptive (OCPs).

CASE REPORT

A 22 – year – old woman, PARA 0000, having regular menstrual period and no previous medical history. She presented with a 2-year history of pruritic erythema which is located only on her back and closely associated with the menstrual period. The red rash became worse 5 days before menstruation and better 3 days after menstruation. A lichenoid papule is on her back, with a size of 15cmx5cm, clearly demarcated, without scabs, and much itching (Figure 1). She didn’t have vaginal bleeding, no history of using cosmetics or chemicals. Blood test results (complete blood count, basic blood chemistry) were within normal limits. An endodermal test with progesterone 50mg/ml was performed for the patient. The results were positive after 20 min both with 1:10 and 1:100 concentrations (Figure 3). The patient was treated with antihistamines (levcertizin 5 mg/day) and methylprednisolone 16 mg/day. After 2 days of treatment, the itchy papule did not improve. The patient was supplemented with Danazol 200mg/day. After 2 days of Danazol treatment, symptoms and redness were significantly reduced (Figure 2). In the following month, with patient taking Danazol 1 week before the period, the rash did not recur.

Figure 1: Lichen papule on the back: red papule, a lot of itching, appearing 5 days before menstruation.

Figure 2: Lichen papules on the back after 7 days of treatment with Danazol: redness and itching significantly reduced.

Figure 3: Skin prick test with Progesterone (concentration 50mg/ml) was negative.

Figure 4: Intradermal test with progesterone (concentration 5mg/ml) was positive after 20 minutes, edema 12 mm

DISCUSSION

Autoimmune progesterone dermatitis is a rare skin condition with varying morphology, appearing on a monthly basis during the luteal phase of the menstrual cycle. Symptoms of APD correlate with progesterone levels during the luteal phase of the menstrual cycle. The first documented case of APD was in 1921, in which a patient’s premenstrual serum caused acute urticarial lesions. In addition, it was shown that the patient’s premenstrual serum could be used to desensitize and improve her symptoms. Progesterone levels gradually rise after ovulation, reaching a peak concentration about 7 days before menstruation, then decreasing 1 to 2 days after menses, when there is a spontaneous resolution of APD.4,5 In this condition, symptoms was found 5 days before menstruation, coincide with the peak progesterone’s concentration. The major mechanism is considered to be the exposure to exogenous and/or endogenous progesterone causing hypersensitivity reaction that leads to clinical manifestation of this disease.1 The pathogenesis of APD remains unclear. Sexhormones modulate the immune and inflammation and inflammatory functions of cells, including mast cell degranulation. Several studies point to an autoimmune mechanism mediated by Th1 lymphocytes targeting endogenous progesterone, as in delayed hypersensitivity reactions. In women undergoing exogenous progesterone prior to APD diagnosis, Th2 cells and immunoglobulin IgE may also play a role.6

The clinical features of APD vary and thus far, about 80 cases have been reported in the literature. The most common clinical manifestations were eczema, urticaria, angioedema and erythema multiforme.5,7,8 Presentation of this case as an eczema is common symptom. Initially, this patient was considered to have allergic contact dermatitis. Because of its polymorphic characteristics, physicians can easily misdiagnose and thus treat this condition incorrectly.

The diagnostic criteria for APD proposed by Warin8 include 1) skin lesion associated with menstrual cycle (premenstrual flare); 2) a positive response to the progesterone intradermal test or reproducibility of the rash with the intramuscular test; and 3) symptomatic improvement after inhibiting progesterone secretion by suppressing ovulation. This patient has full 3 criteria for diagnosis. The intradermal test can support the diagnosis of APD based on the symptoms; on the contrary, in asymptomatic women, a positive intradermal test can result in false negative; therefore, this test might not be the most efficient diagnostic criteria for diagnosis of APD.

Treatment of APD is achieved mainly through suppressing ovulation. The first line of therapy is combined with oral contraceptives. The use of GnRH agonists has been reported successful in treatment. Another therapeutic agent used to suppress ovulation and improve symptoms is tamoxifen.5 Alkylated steroids, such as stanozolol and danazol, have been used to suppress ovulation, occasionally in combination with low dose corticosteroids.9 In this case, we have prescribed danazol to the patient 7 days before each menstrual cycle to 3 days after their period. The patient had a complete response and no relapse.

CONCLUSION

Although the condition is rare, APD should be included in the differential diagnosis in females with a recurrent, cyclical, or recalcitrant cutaneous eruption.

For more information: https://jmedcasereportsimages.org/about-us/

Danazol sunt medicamente pt ginecomastia ce reglează hormonii atunci când nu se dorește o intervenție chirurgicală.

Acesta nu a fost conceput inițial pentru tratarea acestei afecțiuni. În urma studiilor s-a descoperit că ar putea avea un efect de reducere a țesutului tumefiat în zona sânilor.

Cum acționează Danazol?

Danazol este un hormon sintetic( creat în laborator) care are o acțiune complexă în corpul tău.

Principala acțiune care te interesează este creșterea nivelului testosteronului și reducerea nivelului estrogenului( hormonul feminin).  Ginecomastia este strâns legată de nivelul redus de hormon masculin iar Danazol are un efect pozitiv strict pe acest subiect.

Studii privind efectul Danazol pentru tratarea ginecomastiei

Ca și în cazul altor substanțe chimice, s-au făcut câteva studii importante care au arătat că Danazol poate fi folosit cu o rată de succes destul de bună pentru tratamentul acestei afecțiuni.

De exemplu, în acest studiu s-a testat efectul Danazol la ginecomastie copii. La 4 din 15 tineri ce au urmat tratamentul s-au văzut scăderi ale dimensiunii sânilor ( deși nu majore).  În alt studiu, medicii au arătat că Danazol a dat rezultate doar la 40% din bărbații care au urmat un tratament cu acest hormon.

Merită tratamentul ginecomastiei cu Danazol?

În plus pot apărea efecte secundare foarte neplăcute pentru că vorbim de un efect complex asupra sistemului hormonal.

Printre efectele adverse cunoscute ca frecvente la consumul de Danazol se numără — creșterea în greutate, acnee, pierderea părului, depresie și altele asemănătoare.

Acum nu este obligatoriu ca tu să ai aceste efecte, dar trebuie să discuți cu un medic endocrinolog capabil care să știe cât mai multe informații despre medicament.

Concluzie

Ca și medicamentul Tamoxifen, Danazol este un hormon chimic care are peste 40 de ani de la lansare. Este folosit în lipsă de alternative mai sigure și are o rată de succes mediocră când te interesează reducerea sânilor bărbătești.

Alternativă